SCHEMBL7125772

SCHEMBL7125772

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@H]1CN1CC[C@H](F)C1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.87
FGFR1 P11362 10/20 0.87
PDGFRB P09619 10/20 0.87
MET P08581 7/20 0.87
SRC P12931 6/20 0.87
LCK P06239 5/20 0.87
YES1 P07947 5/20 0.87
CDK2 P24941 2/20 0.87
PTK2B Q14289 2/20 0.87
MEN1 O00255 2/20 0.87
KMT2A Q03164 2/20 0.87
TDP1 Q9NUW8 2/20 0.87
KIT P10721 2/20 0.87
EGFR P00533 2/20 0.87
ALK Q9UM73 2/20 0.87
PLK4 O00444 1/20 0.87
RIOK3 O14730 1/20 0.87
CASK O14936 1/20 0.87
GAK O14976 1/20 0.87
DCLK1 O15075 1/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147210 1.00 KDR (0.87) KDRFGFR1PDGFRBMETSRC
SCHEMBL143939 1.00 KDR (0.87) KDRFGFR1PDGFRBMETSRC
SCHEMBL145952 0.98 KDR (0.88) KDRFGFR1PDGFRBMETSRC
SCHEMBL147331 0.96 KDR (0.91) KDRFGFR1PDGFRBMETSRC
SCHEMBL6267151 0.96 KDR (0.91) KDRFGFR1PDGFRBMETSRC
SCHEMBL146729 0.94 KDR (0.88) KDRFGFR1PDGFRBMETSRC
SCHEMBL144319 0.94 KDR (0.88) KDRFGFR1PDGFRBMETSRC
SCHEMBL144192 0.93 KDR (0.75) KDRFGFR1PDGFRBMETSRC
SCHEMBL143795 0.93 KDR (0.93) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93657 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885FGFR1 637/4885PDGFRB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.